指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

强化血糖控制目标与常规血糖控制目标的比较:2024年美国重症医学会重症成人血糖控制指南的更新系统评价与Meta分析

Comparison of Intensive Versus Conventional Glycemic Control Targets: An Updated Systematic Review and Meta-Analysis of the 2024 Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Adults.
指南 / 共识 · Crit Care Med · 2026-06-09
一句话结论强化血糖目标与常规目标相比不降低ICU或住院死亡率,但严重低血糖风险升高3.6倍;美国重症医学会指南认为在低血糖风险可忽略的选择性中心可考虑强化范围内较低目标(110-140 mg/dL;6.1-7.8 mmol/L)。

该更新系统评价与Meta分析纳入45项随机对照试验、共32215例接受胰岛素输注的成人重症患者,比较强化与常规血糖控制目标的疗效与安全性。强化目标未降低ICU死亡率或住院死亡率,但与更低的ICU住院时间、感染和危重病性多神经病相关,同时严重低血糖风险升高3.6倍。多数有显著差异的研究存在严重不一致或偏倚风险。亚组分析中,强化目标在神经ICU患者中显示有利的神经功能结局,在混合ICU患者中降低ICU住院时间,在心脏外科亚组中降低ICU死亡率。美国重症医学会指南指出,在低血糖风险经评估可忽略且使用优化血糖管理方案的选择性中心,可考虑强化范围内较低目标(110-140 mg/dL;6.1-7.8 mmol/L)。

要点

  • 45项RCT、32215例成人重症患者:强化与常规血糖目标相比,ICU死亡率和住院死亡率无差异。
  • 强化血糖目标与严重低血糖风险升高3.6倍相关,不应常规用于以低血糖作为患者安全指标的场景。
  • 强化目标与更低的ICU住院时间、感染和危重病性多神经病相关,但多数有显著差异的研究存在严重不一致或偏倚风险。
  • 亚组分析:神经ICU患者强化目标显示有利神经功能结局,混合ICU患者ICU住院时间更低,心脏外科亚组ICU死亡率更低。
  • 美国重症医学会指南:在低血糖风险经评估可忽略且使用优化血糖管理方案的选择性中心,可考虑强化范围内较低目标(110-140 mg/dL;6.1-7.8 mmol/L)。

适用人群与场景

  • 接受胰岛素输注的成人重症患者(纳入随机对照试验的人群)。

诊断标准与关键阈值

  • 强化血糖目标范围内较低目标为110-140 mg/dL(6.1-7.8 mmol/L),仅限低血糖风险经评估可忽略且使用优化血糖管理方案的选择性中心可考虑。

处置流程与药物剂量

  • 美国重症医学会指南指出,在低血糖风险经常规评估证实可忽略且使用优化血糖管理方案的选择性中心,可考虑强化范围内较低目标(110-140 mg/dL;6.1-7.8 mmol/L)。
  • 强化血糖目标不应常规优先于常规目标使用,以减少低血糖作为患者安全指标。

研究设计与关键结果

  • 更新系统评价与Meta分析纳入45项RCT、32215例接受胰岛素输注的成人重症患者,比较强化与常规血糖目标。
  • 强化与常规目标相比,住院死亡率和ICU死亡率无差异。
  • 强化目标与更低的ICU住院时间、感染和危重病性多神经病相关。
  • 强化目标与严重低血糖风险升高3.6倍相关。
  • 多数有显著差异的研究存在严重不一致或偏倚风险。
  • 亚组分析:神经ICU患者强化目标显示有利神经功能结局;混合ICU患者ICU住院时间更低;心脏外科亚组ICU死亡率更低。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(纳入45项随机对照试验),为2024年美国重症医学会重症成人血糖控制指南的更新系统评价。
  • 局限:多数有显著差异的研究存在严重不一致或偏倚风险。

对床旁实践的改变

  • 强化血糖目标不应常规优先于常规目标使用,以减少低血糖作为患者安全指标。
  • 在低血糖风险经评估可忽略且使用优化血糖管理方案的选择性中心,可考虑强化范围内较低目标(110-140 mg/dL;6.1-7.8 mmol/L)。
  • 神经ICU患者、混合ICU患者和心脏外科亚组中强化目标的潜在获益来自亚组分析,多数有显著差异的研究存在严重不一致或偏倚风险。

指南或共识出处

  • 2024年美国重症医学会(Society of Critical Care Medicine)重症成人血糖控制指南。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To perform an updated systematic review and meta-analysis of the efficacy and safety of intensive (INT) vs. conventional (CONV) blood glucose (BG) targets for critically ill adults on insulin infusions.

DATA SOURCES: We conducted a comprehensive search of Embase and OVID Medline databases from inception to October 16, 2023. We manually excluded studies published before 2000 due to potential lack of relevance as glycemic control in the ICU was not routinely practiced before 2000.

STUDY SELECTION: We included randomized controlled trials (RCTs) evaluating adult, critically ill patients on insulin infusions comparing INT vs. CONV targets for efficacy and safety outcomes.

DATA EXTRACTION: Data were screened and extracted with accuracy confirmed by a second reviewer. Study methodological characteristics, patient population, interventions, and outcome data were recorded. Studies without numerical outcomes were summarized as text statements.

DATA SYNTHESIS: Forty-five RCTs were included involving 32,215 patients. No differences were seen between INT and CONV targets for hospital mortality or ICU mortality. INT targets were associated with lower ICU length of stay (LOS), infections, and critical illness polyneuropathy (CIP); however, INT targets demonstrated a 3.6-fold higher risk of severe hypoglycemia. Most of the studies with significant differences contained serious inconsistencies or risk of bias. In the subgroup analyses, INT targets demonstrated favorable neurologic outcomes in neurologic ICU patients, lower ICU LOS in mixed ICU patients, and lower ICU mortality in the cardiac surgery subgroup.

CONCLUSIONS: INT BG targets demonstrated mild to moderate improvements in several important morbidity secondary outcomes, including LOS, infections, and CIP, but were associated with a 3.6-fold higher risk of severe hypoglycemia. No differences were seen in ICU or hospital mortality. INT targets should not be routinely used over CONV targets when trying to minimize hypoglycemia as a marker of patient safety. However, as stated in the Society of Critical Care Medicine guidelines, a lower target within the INT range (110-140 mg/dL; 6.1-7.8 mmol/L) may be considered acceptable in select centers where the risk of hypoglycemia is documented to be negligible based on routine assessment and with the use of optimized glycemic management protocols.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Sirimaturos M, Honarmand K, Long MT, et al. Comparison of Intensive Versus Conventional Glycemic Control Targets: An Updated Systematic Review and Meta-Analysis of the 2024 Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Adults. Crit Care Med. 2026. PMID: 42262517. doi:10.1097/CCM.0000000000007175

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。